RPTX Repare Therapeutics Inc
Price (delayed)
$0.9999
Market cap
$42.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
-$40.28M
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled
Highlights
RPTX's debt is down by 43% year-on-year and by 25% since the previous quarter
RPTX's EPS is up by 10% YoY
Repare Therapeutics's gross profit has decreased by 20% from the previous quarter but it has increased by 4.6% YoY
Repare Therapeutics's revenue has decreased by 20% from the previous quarter but it has increased by 4.6% YoY
The equity has contracted by 29% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of RPTX
Market
Valuations
Earnings
Shares outstanding
42.51M
Market cap
$42.51M
Enterprise value
-$40.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
0.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.75
Revenue
$53.48M
Gross profit
$53.48M
Operating income
-$93.52M
Net income
-$84.69M
EBIT
-$83.25M
EBITDA
-$78.97M
Free cash flow
-$76.45M
Per share
Balance sheet
Liquidity
EPS
-$2
EPS diluted
-$2
Free cash flow per share
-$1.8
Book value per share
$3.56
Revenue per share
$1.26
TBVPS
$4.16
Total assets
$176.51M
Total liabilities
$25.38M
Debt
$1.93M
Equity
$151.13M
Working capital
$145.86M
Debt to equity
0.01
Current ratio
6.77
Quick ratio
6.11
Net debt/EBITDA
1.05
Margins
Efficiency
Dividend
EBITDA margin
-147.7%
Gross margin
100%
Net margin
-158.4%
Operating margin
-174.9%
Return on assets
-38.4%
Return on equity
-44.5%
Return on invested capital
-78.5%
Return on capital employed
-55.1%
Return on sales
-155.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RPTX stock price
How has the Repare Therapeutics stock price performed over time
Intraday
-4.77%
1 week
-4.77%
1 month
-14.54%
1 year
-74.36%
YTD
-23.67%
QTD
1.42%
Financial performance
How have Repare Therapeutics's revenue and profit performed over time
Revenue
$53.48M
Gross profit
$53.48M
Operating income
-$93.52M
Net income
-$84.69M
Gross margin
100%
Net margin
-158.4%
RPTX's net margin is down by 25% since the previous quarter but it is up by 14% year-on-year
Repare Therapeutics's operating margin has decreased by 24% QoQ but it has increased by 23% YoY
RPTX's operating income is up by 20% YoY
Repare Therapeutics's gross profit has decreased by 20% from the previous quarter but it has increased by 4.6% YoY
Growth
What is Repare Therapeutics's growth rate over time
Valuation
What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.28
P/S
0.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.75
RPTX's EPS is up by 10% YoY
The P/B is 89% below the 5-year quarterly average of 2.5 and 60% below the last 4 quarters average of 0.7
The equity has contracted by 29% YoY and by 14% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 721.9 and 56% lower than the last 4 quarters average of 1.8
Repare Therapeutics's revenue has decreased by 20% from the previous quarter but it has increased by 4.6% YoY
Efficiency
How efficient is Repare Therapeutics business performance
RPTX's ROS is down by 26% from the previous quarter but it is up by 23% YoY
The ROA has contracted by 21% YoY and by 9% from the previous quarter
RPTX's return on equity is down by 12% year-on-year and by 9% since the previous quarter
Repare Therapeutics's ROIC has decreased by 10% from the previous quarter
Dividends
What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RPTX.
Financial health
How did Repare Therapeutics financials performed over time
Repare Therapeutics's total liabilities has decreased by 39% YoY and by 19% QoQ
The company's total assets fell by 30% YoY and by 14% QoQ
RPTX's debt is 99% smaller than its equity
The debt to equity has dropped by 50% year-on-year
RPTX's debt is down by 43% year-on-year and by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.